- Home
- CRVS vs HFRO Comparison
CRVS vs HFRO Comparison
Compare CRVS & HFRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- HFRO
- Stock Information
- Founded
- CRVS 2014
- HFRO 2000
- Country
- CRVS United States
- HFRO United States
- Employees
- CRVS N/A
- HFRO N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- HFRO Finance/Investors Services
- Sector
- CRVS Health Care
- HFRO Finance
- Exchange
- CRVS Nasdaq
- HFRO Nasdaq
- Market Cap
- CRVS 305.4M
- HFRO 287.7M
- IPO Year
- CRVS 2016
- HFRO N/A
- Fundamental
- Price
- CRVS $5.55
- HFRO $6.13
- Analyst Decision
- CRVS Strong Buy
- HFRO
- Analyst Count
- CRVS 4
- HFRO 0
- Target Price
- CRVS $15.00
- HFRO N/A
- AVG Volume (30 Days)
- CRVS 461.1K
- HFRO 179.8K
- Earning Date
- CRVS 08-07-2025
- HFRO 01-01-0001
- Dividend Yield
- CRVS N/A
- HFRO 8.87%
- EPS Growth
- CRVS N/A
- HFRO N/A
- EPS
- CRVS N/A
- HFRO N/A
- Revenue
- CRVS N/A
- HFRO N/A
- Revenue This Year
- CRVS N/A
- HFRO N/A
- Revenue Next Year
- CRVS N/A
- HFRO N/A
- P/E Ratio
- CRVS N/A
- HFRO N/A
- Revenue Growth
- CRVS N/A
- HFRO N/A
- 52 Week Low
- CRVS $2.54
- HFRO $4.24
- 52 Week High
- CRVS $10.00
- HFRO $6.45
- Technical
- Relative Strength Index (RSI)
- CRVS 69.70
- HFRO 82.02
- Support Level
- CRVS $5.03
- HFRO $5.97
- Resistance Level
- CRVS $5.81
- HFRO $6.04
- Average True Range (ATR)
- CRVS 0.32
- HFRO 0.08
- MACD
- CRVS 0.09
- HFRO 0.02
- Stochastic Oscillator
- CRVS 85.22
- HFRO 100.00
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About HFRO Highland Opportunities and Income Fund of Beneficial Interest
Highland Opportunities and Income Fund is a non-diversified, closed-end management investment company. Its investment objective is to Income Fund seeks growth of capital along with income. It focuses on making investments in real estate securities, including Reits, secured and unsecured fixed-rate loans and corporate bonds, mezzanine securities, structured products, convertible and preferred securities and equities (public and private), and floating rate securities.